Condition: Persistent Corneal Epithelial Defect · Corneal Epithelial Disorders · Sponsor: University of Illinois at Chicago
In this phase II randomized double-masked clinical trials, subjects with non-resolving corneal epithelial disease/defect (i.e., refractory to standard treatments for at least two weeks) will receive 8 weeks treatment of topical mesenchymal stem cell secretome or vehicle, with continued follow-up for up to Day 70.
This description comes directly from the study's public registry record.
Ali R Djalilian, MD · 3129968937 · adjalili@uic.edu
Charlotte E Joslin, OD · 3129965410 · charjosl@uic.edu
Always discuss trial participation with your own doctor first.
| University of Illinois at Chicago | Chicago, Illinois, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06919081